Noradrenergic system in the pathogenesis of age-dependent neurodegeneration

Ageing & Longevity, Journal Year: 2025, Volume and Issue: 1.2025, P. 28 - 34

Published: Jan. 28, 2025

Ageing is a key factor in the development of cognitive decline and neurodegeneration, including Alzheimer’s disease (AD), most common form dementia diagnosed. In 2023 US Federal Drug Administration (FDA) approved new drug (Lecanemab, Leqembi) to treat AD that very moderately slows down early-stage (van Dyck et al., 2023). Donanemab (Kisunla, Eli Lilley), acting similarly lecanemab, was by FDA 2024 US, but not yet European Medicines Agency (EMA) EU. The mechanism action both these monoclonal antibodies similar aducanumab (Aduhelm), conditionally for 2021 (but subsequently discontinued producer), on reducing β-amyloid deposits (Sevigny 2016; van However, trials all revealed significant adverse events (brain swelling or brain bleeding); hence treatment neurodegeneration general remains an important unmet medical need, affecting millions people worldwide. Here I discuss role noradrenergic system innervating spinal cord, consisting nucleus locus coeruleus (LC), which appears be vulnerable structure central nervous (CNS) ageing-related factors, leading early LC demise impairments. Therefore, propose understanding noradrenaline cells, particular astrocytes, homeostasis-providing exhibit high density adrenergic receptors, future strategy develop drugs mitigate decline. Keywords: ageing; noradrenaline; adrenoceptors; coeruleus; neuroglia, astrocytes

Language: Английский

Prefrontal-hippocampal pathways underlying adolescent resilience

European Child & Adolescent Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Language: Английский